Pancreatic Cancer Research

ResearcherOita UniversityActive in the last 2 years

Masafumi Inomata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8475-3688; OpenAlex author ID A5102021057. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 16

  1. Annexin A8 Drives MEK Inhibitor Resistance, Providing a Druggable Target for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-25-0638↗
  2. Pancreatoduodenectomy for Pancreatic Cancer after Prior Modified Puestow Procedure: A Case Report. Last author DOI 10.70352/scrj.cr.25-0821↗
  3. Ectopic Pancreatic Adenocarcinoma Arising in the Mesentery of the Jejunum: A Case Report. Last author DOI 10.70352/scrj.cr.26-0120↗
  4. Pancreatic Cancer with Concomitant Median Arcuate Ligament Syndrome Requiring Arterial Reconstruction During Pancreaticoduodenectomy: A Case Report. Last author DOI 10.70352/scrj.cr.26-0185↗
  5. Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma. Last author DOI 10.3892/mco.2024.2813↗
  6. Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor. Co-author DOI 10.1111/cas.15735↗
  7. Technical and oncological safety of pancreatectomy for pancreatic cancer in older adults aged over 75 years versus younger adults: A single-center retrospectiv… Last author DOI 10.1111/ggi.14622↗
  8. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  9. Surgical and oncological outcomes of laparoscopic versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-021-02326-1↗
  10. Relationship between the tumor location and clinicopathological features in left-sided pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-020-02151-y↗
  11. Downregulation of ZNF395 Drives Progression of Pancreatic Ductal Adenocarcinoma through Enhancement of Growth Potential. Co-author DOI 10.1159/000514593↗
  12. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… Co-author DOI 10.29337/ijsp.142↗
  13. [Long‒Term Survival after Lung Resection for Lung Metastasis of Pancreatic Cancer-A Report of Two Cases]. Last author PMID 34006715↗
  14. Fucosyltransferase 8 plays a crucial role in the invasion and metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-019-01953-z↗
  15. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  16. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Co-author DOI 10.1007/s00535-018-01535-9↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teijiro Hirashita · 12 shared papers, 2020–2026 · strength 2.29
  2. Yuiko Nagasawa · 4 shared papers, 2025–2026 · strength 1.09
  3. Wataru Miyoshino · 3 shared papers, 2026 · strength 0.85
  4. Atsuro Fujinaga · 5 shared papers, 2021–2025 · strength 0.84
  5. Naoki Hijiya · 3 shared papers, 2021–2026 · strength 0.51
  6. Masatsugu Moriyama · 3 shared papers, 2021–2026 · strength 0.51
  7. Shusaku Kurogi · 3 shared papers, 2021–2026 · strength 0.51
  8. Kazuhiro Tada · 3 shared papers, 2020–2025 · strength 0.49
  9. Kazuyoshi Nishihara · 3 shared papers, 2019–2023 · strength 0.34
  10. Susumu Eguchi · 3 shared papers, 2019–2023 · strength 0.34
  11. Hirokazu Noshirο · 3 shared papers, 2019–2023 · strength 0.34
  12. Yoshihiro Miyasaka · 3 shared papers, 2019–2023 · strength 0.34
  13. Takao Ohtsuka · 3 shared papers, 2019–2023 · strength 0.34
  14. Izuru Furusho · 1 shared paper, 2026 · strength 0.27
  15. Tsutomu Daa · 1 shared paper, 2026 · strength 0.27
  16. Hiroaki Nagano · 2 shared papers, 2021–2023 · strength 0.27
  17. Masafumi Nakamura · 2 shared papers, 2021–2023 · strength 0.27
  18. Kazunari Murakami · 2 shared papers, 2021–2023 · strength 0.25
  19. Hiroshi Kurahara · 2 shared papers, 2019–2023 · strength 0.22
  20. Hideo Baba · 2 shared papers, 2019–2023 · strength 0.22
  21. Hideo Baba · 2 shared papers, 2019–2021 · strength 0.20
  22. Akira Chikamoto · 2 shared papers, 2019 · strength 0.15
  23. Toru Hisaka · 1 shared paper, 2023 · strength 0.15
  24. Kousei Ishigami · 1 shared paper, 2023 · strength 0.15
  25. Kohei Nakata · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.